These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15964286)

  • 21. Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.
    Beasley A; White KO; Cremers S; Westhoff C
    Contraception; 2014 May; 89(5):352-6. PubMed ID: 24656555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians.
    Paschall S; Kaunitz AM
    Contraception; 2008 Nov; 78(5):370-6. PubMed ID: 18929733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood.
    Kohn JE; Simons HR; Della Badia L; Draper E; Morfesis J; Talmont E; Beasley A; McDonald M; Westhoff CL
    Contraception; 2018 Mar; 97(3):198-204. PubMed ID: 29246818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal.
    Burke HM; Mueller MP; Perry B; Packer C; Bufumbo L; Mbengue D; Mall I; Daff BM; Mbonye AK
    Contraception; 2014 May; 89(5):361-7. PubMed ID: 24631328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Not FDA-approved, but experts recommend Depo-Provera.
    Contracept Technol Update; 1992 Jan; 13(1):1-7. PubMed ID: 12343458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaginal estrogen supplementation during Depo-Provera initiation: a randomized controlled trial.
    Dempsey A; Roca C; Westhoff C
    Contraception; 2010 Sep; 82(3):250-5. PubMed ID: 20705153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA advisory panel recommends approval for Depo-Provera.
    Contracept Technol Update; 1992 Oct; 13(10):159-60. PubMed ID: 12344726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New year, new option: Cyclo-Provera awaits word.
    Contracept Technol Update; 1998 Jan; 19(1):3-4. PubMed ID: 12348212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Injectable contraception.
    International Planned Parenthood Federation IPPF. International Medical Advisory Panel IMAP
    IPPF Med Bull; 1980 Dec; 14(6):1-3. PubMed ID: 12310087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of training in effective simulated self-injection of subcutaneous depot medroxyprogesterone acetate: observations from a usability study.
    Kaplan I; Ross D; Hilton F; Morgenstern D; Wolter K
    Contraception; 2016 Oct; 94(4):314-20. PubMed ID: 27241898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Client and provider experiences with self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Malawi.
    Burke HM; Packer C; Buluzi M; Healy E; Ngwira B
    Contraception; 2018 Nov; 98(5):405-410. PubMed ID: 29706227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Depot medroxyprogesterone acetate (DMPA) injectable contraception--safe, effective but neglected method of family planning in Poland].
    Lech MM
    Wiad Lek; 2003; 56(7-8):362-8. PubMed ID: 14969166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The contraceptive use of Depo-Provera in U.S. adolescents.
    Pinkston Koenigs LM; Miller NH
    J Adolesc Health; 1995 May; 16(5):347-9. PubMed ID: 7662682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Injectable contraception: the USA perspective.
    Kaunitz AM
    IPPF Med Bull; 1992 Dec; 26(6):1-3. PubMed ID: 12346920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pretreatment counseling keeps patients on Depo.
    Contracept Technol Update; 1997 Oct; 18(10):125-6. PubMed ID: 12321212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immediate monthly combination contraception to facilitate initiation of the depot medroxyprogesterone acetate contraceptive injection.
    Morroni C; Grams M; Tiezzi L; Westhoff C
    Contraception; 2004 Jul; 70(1):19-23. PubMed ID: 15208048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women.
    Williams RL; Hensel DJ; Fortenberry JD
    Contraception; 2013 Sep; 88(3):401-7. PubMed ID: 23294549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera.
    Halpern V; Brache V; Taylor D; Lendvay A; Cochón L; Jensen JT; Dorflinger LJ
    Fertil Steril; 2021 Apr; 115(4):1035-1043. PubMed ID: 33485608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicology of depot medroxyprogesterone acetate.
    Jordan A
    Contraception; 1994 Mar; 49(3):189-201. PubMed ID: 8200213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What is breast cancer risk with Depo-Provera?
    Contracept Technol Update; 1992 Jan; 13(1):15-6. PubMed ID: 12343459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.